1. Home
  2. MDGL vs HQY Comparison

MDGL vs HQY Comparison

Compare MDGL & HQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • HQY
  • Stock Information
  • Founded
  • MDGL 2011
  • HQY 2002
  • Country
  • MDGL United States
  • HQY United States
  • Employees
  • MDGL N/A
  • HQY N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • HQY Business Services
  • Sector
  • MDGL Health Care
  • HQY Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • HQY Nasdaq
  • Market Cap
  • MDGL 9.6B
  • HQY 7.9B
  • IPO Year
  • MDGL N/A
  • HQY 2014
  • Fundamental
  • Price
  • MDGL $423.00
  • HQY $93.83
  • Analyst Decision
  • MDGL Strong Buy
  • HQY Strong Buy
  • Analyst Count
  • MDGL 12
  • HQY 15
  • Target Price
  • MDGL $521.09
  • HQY $119.93
  • AVG Volume (30 Days)
  • MDGL 277.8K
  • HQY 845.3K
  • Earning Date
  • MDGL 11-04-2025
  • HQY 12-08-2025
  • Dividend Yield
  • MDGL N/A
  • HQY N/A
  • EPS Growth
  • MDGL N/A
  • HQY 37.24
  • EPS
  • MDGL N/A
  • HQY 1.65
  • Revenue
  • MDGL $515,547,000.00
  • HQY $1,268,928,000.00
  • Revenue This Year
  • MDGL $394.38
  • HQY $10.27
  • Revenue Next Year
  • MDGL $64.73
  • HQY $8.24
  • P/E Ratio
  • MDGL N/A
  • HQY $57.37
  • Revenue Growth
  • MDGL 3421.98
  • HQY 15.45
  • 52 Week Low
  • MDGL $213.71
  • HQY $74.07
  • 52 Week High
  • MDGL $463.63
  • HQY $116.65
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 46.03
  • HQY 52.29
  • Support Level
  • MDGL $413.82
  • HQY $93.35
  • Resistance Level
  • MDGL $436.79
  • HQY $97.72
  • Average True Range (ATR)
  • MDGL 18.12
  • HQY 2.57
  • MACD
  • MDGL -2.63
  • HQY 0.28
  • Stochastic Oscillator
  • MDGL 48.76
  • HQY 63.47

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About HQY HealthEquity Inc.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Share on Social Networks: